Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Herceptin (trastuzumab) is a prescription drug that’s used to treat certain types of breast cancer and stomach cancer. Herceptin can cause side effects that range from mild to serious.

When Trastuzumab (Herceptin®) was added, 373 survived, but 35 developed heart problems that required immediate discontinuation of Trastuzumab. These cardiac dysfunctions were usually reversible ...

Patients were randomly assigned, in a 1:1 ratio, to receive placebo plus trastuzumab (Herceptin, F. Hoffmann–La Roche/Genentech) plus docetaxel or pertuzumab (F. Hoffmann–La Roche/Genentech ...

Authors of the study, published in the cancer journal, Annals of Oncology on August 10, looked at records for 45 women aged between 70 and 92 who had been treated with trastuzumab since 2005 and ...

The Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-overexpressing breast cancer. The Food and Drug Administration ...

Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery.

What are its potential side effects versus benefits? Answer: Herceptin is a drug, an agent whose chemical name is 'trastuzumab.' It's a monoclonal antibody that interferes with the function of an ...

13, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that Health Canada has approved a subcutaneous formulation of HERCEPTIN for the treatment of early and metastatic stage ...

Five major clinical trials have evaluated trastuzumab (Herceptin, Genentech) use in the adjuvant setting for breast cancer. Important similarities exist within these trials. All of these studies ...